BETR BETTERLIFE PHARMA INC.

CNQ · CA · Healthcare · Biotechnology · abetterlifepharma.com

0.2650CAD-1.85%Mkt Cap: 119.27M $P/E: —3d ago

BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative …

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap119.27M USD

Enterprise Value123.06M USD

Revenue (TTM)—

Gross Profit—

Net Income (TTM)-1.09M USD

Revenue/Share—

Last Price0.2650 CAD

Fiscal Year EndJan 2026

MR QuarterJul 2026

Employees—

CountryCA

SectorHealthcare

IndustryBiotechnology

ISINCA08772P2026

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue—

P/S—

P/B-4.42

EPS (TTM)-0.03

EPS (Forward)—

52W Range

0.040071% of range0.3550

52W High0.3550 CAD

52W Low0.0400 CAD

Profitability

Gross Margin0.00%

Oper. Margin0.00%

EBITDA Margin0.00%

Profit Margin0.00%

ROE15.28%

ROA-680.07%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-455.49K USD

CapEx (TTM)—

FCF Margin—

FCF Yield-0.29%

Net Debt1.40M USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity-0.13

Current Ratio0.21

Quick Ratio0.11

Book Value/Sh-0.06 CAD

Cash/Share0.0020 CAD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 CAD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:10

Split DateJun 26, 2020

Analyst Consensus

Rating—

Target (Mean)—

Target Range—

# Analysts—

Ownership

Shares Out.618.01M

Float507.41M

Insiders8.92%

Institutions8.97%

Short Interest

Short Ratio13.5d

Short % Float5.18%

Short % Out.3.57%

Shares Short6.11M

Short (prev mo.)42.44K

Technical

SMA 500.3138 (-15.6%)

SMA 2000.1362 (+94.5%)

Beta0.22

S&P 52W Chg14.58%

Avg Vol (30d)248.67K

Avg Vol (10d)428.00K

Technical Indicators

RSI (14)52.2

MACD0.0332

MACD Signal0.0390

MACD Hist.-0.0058

BB Upper0.3685 CAD

BB Middle0.2690 CAD

BB Lower0.1695 CAD

BB Width73.94%

ATR (14)0.0305 CAD

Vol Ratio (20d)1.36x